Spotlight on Infectious Diseases

Credits: 1.00 CME / CNE
HIV and CVD: Beyond Coronary Heart Disease
Gerald Bloomfield, MD, MPH, FACC, FASE, FAHA
American Heart Association

HIV and CVD: Beyond Coronary Heart Disease

Start

Accredited By

American Heart Association

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: September 21, 2017
Expires: September 21, 2020
60 minutes to complete

Target Audience

Physicians (Cardiology, Family Practice, Infectious Disease, HIV Specialist and Internal Medicine); Physician Assistants (Cardiology, Family Practice, Infectious Disease, HIV Specialist, and Internal Medicine); Nurses/Nurse Practitioners; Other (Clinicians involved in the treatment and management of patients with HIV/AIDS)

Learning Objectives

1) Describe the general epidemiology of cardiovascular disease (CVD) related complications of human immunodeficiency virus (HIV) 2) Describe risk factors and mechanisms of atherosclerotic CVD in HIV 3) Describe approaches to predict, prevent, and treat atherosclerotic CVD in HIV 4) Review the scope of non-atherosclerotic CVD in HIV, as well as related mechanisms and treatment approaches

Activity Description

The program reviews epidemiologic patterns in HIV and the relevance of these for understanding the scope of CVD among HIV-infected individuals. Important concepts related to atherosclerotic and non-atherosclerotic cardiovascular diseases in people living with HIV, focusing on heart failure, arrhythmias and sudden cardiac death will be discussed; including new developments and existing barriers regarding CVD treatment for HIV-infected individuals.

Statement of Educational Need

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Agenda

45 minutes - HIV and CVD: Beyond Coronary Heart Disease Presentation

15 minutes – Q & A

Presenters

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Assistant Professor of Medicine & Global Health
Director, Cardiovascular Global Health
Duke University Medical Center
Duke Clinical Research Institute
Durham, NC 27705


Matthew S. Freiberg, MD, MSc
Director, Vanderbilt Center for Clinical Cardiovascular outcomes
Research And Trials Evaluation (V-C3REATE)
West End Home Foundation Scholar
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN


Planning Committee (Content Developers)

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Matthew J. Feinstein, MD
Matthew S. Freiberg, MD, MSc
Mark J. Haykowsky, PhD
Priscilla Hsue, MD
Wendy S. Post, MD, MS
David G. Weismiller, MD ScM, FAAFP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA – No Disclosures
Matthew J. Feinstein, MD – No Disclosures
Matthew S. Freiberg, MD, MSc – No Disclosures
Mark J. Haykowsky, PhD – No Disclosures
Priscilla Hsue, MD – Honoraria – Gilead; Research Grant – Pfizer; Other Research Support – Novartis
Wendy S. Post, MD, MS – No Disclosures
David G. Weismiller, MD ScM, FAAFP – No Disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/21/2017

TERMINATION DATE: 09/21/2020

LAST REVIEW DATE: June 2017

JOINT ACCREDITATION TERM: 09/21/2017 – 09/21/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

AAFP Credit Statement - Physicians
This Enduring Material activity, HIV and CVD: Beyond Coronary Heart Disease, has been reviewed and is acceptable for up to 1.0 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 09/21/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation and Successful Completion

Successful completion of this CE activity includes the following: 

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 80%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Gilead Sciences.

Disclaimer Statement/ Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Luci Ochoa, MBA
Manager, Lifelong Learning, AHA National Center
luci.ochoa@heart.org

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Accredited By

American Heart Association

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: September 21, 2017
Expires: September 21, 2020
60 minutes to complete

Target Audience

Physicians (Cardiology, Family Practice, Infectious Disease, HIV Specialist and Internal Medicine); Physician Assistants (Cardiology, Family Practice, Infectious Disease, HIV Specialist, and Internal Medicine); Nurses/Nurse Practitioners; Other (Clinicians involved in the treatment and management of patients with HIV/AIDS)

Learning Objectives

1) Describe the general epidemiology of cardiovascular disease (CVD) related complications of human immunodeficiency virus (HIV) 2) Describe risk factors and mechanisms of atherosclerotic CVD in HIV 3) Describe approaches to predict, prevent, and treat atherosclerotic CVD in HIV 4) Review the scope of non-atherosclerotic CVD in HIV, as well as related mechanisms and treatment approaches

Activity Description

The program reviews epidemiologic patterns in HIV and the relevance of these for understanding the scope of CVD among HIV-infected individuals. Important concepts related to atherosclerotic and non-atherosclerotic cardiovascular diseases in people living with HIV, focusing on heart failure, arrhythmias and sudden cardiac death will be discussed; including new developments and existing barriers regarding CVD treatment for HIV-infected individuals.

Statement of Educational Need

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Agenda

45 minutes - HIV and CVD: Beyond Coronary Heart Disease Presentation

15 minutes – Q & A

Presenters

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Assistant Professor of Medicine & Global Health
Director, Cardiovascular Global Health
Duke University Medical Center
Duke Clinical Research Institute
Durham, NC 27705


Matthew S. Freiberg, MD, MSc
Director, Vanderbilt Center for Clinical Cardiovascular outcomes
Research And Trials Evaluation (V-C3REATE)
West End Home Foundation Scholar
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN


Planning Committee (Content Developers)

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Matthew J. Feinstein, MD
Matthew S. Freiberg, MD, MSc
Mark J. Haykowsky, PhD
Priscilla Hsue, MD
Wendy S. Post, MD, MS
David G. Weismiller, MD ScM, FAAFP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA – No Disclosures
Matthew J. Feinstein, MD – No Disclosures
Matthew S. Freiberg, MD, MSc – No Disclosures
Mark J. Haykowsky, PhD – No Disclosures
Priscilla Hsue, MD – Honoraria – Gilead; Research Grant – Pfizer; Other Research Support – Novartis
Wendy S. Post, MD, MS – No Disclosures
David G. Weismiller, MD ScM, FAAFP – No Disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/21/2017

TERMINATION DATE: 09/21/2020

LAST REVIEW DATE: June 2017

JOINT ACCREDITATION TERM: 09/21/2017 – 09/21/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

AAFP Credit Statement - Physicians
This Enduring Material activity, HIV and CVD: Beyond Coronary Heart Disease, has been reviewed and is acceptable for up to 1.0 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 09/21/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation and Successful Completion

Successful completion of this CE activity includes the following: 

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 80%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Gilead Sciences.

Disclaimer Statement/ Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Luci Ochoa, MBA
Manager, Lifelong Learning, AHA National Center
luci.ochoa@heart.org

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Infectious Diseases Presentations

0.75 CME
Vindico
What’s New in Flu? Advances in Therapeutic Options

What’s New in Flu? Advances in Therapeutic Options

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: January 15, 2020
Expires: January 14, 2021
45 minutes to complete

Provided By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is emergency medicine physicians and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate diagnostic assays into practice that have demonstrated improved sensitivity, specificity, and convenience to improve the detection of influenza.
  • Implement effective practices and procedures that reduce the spread of influenza in the hospital setting.
  • Utilize therapeutic regimens that effectively treat influenza as well as reduce its complications.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of children and adults in the United States each year. Emergency departments are a frequent point of entry for many influenza cases and are well-positioned to identify and manage influenza community outbreaks and epidemics. Clinical trials and observational data show that early antiviral treatment can shorten the duration of fever and illness symptoms and may reduce the risk of complications from influenza. Three classes of antiviral drugs are currently available for the prevention and treatment of influenza: neuraminidase inhibitors, adamantanes, and the polymerase inhibitor baloxavir marboxil. The faculty of this CME activity will explore existing and newer diagnostic methods for influenza as well as approved antiviral agents regarding their novel mechanisms of action, ability to reduce duration of clinical illness and complications, and cessation of viral shedding.

Agenda

Diagnosing Flu in the ED – Jason E. Bowling, MD
Case Presentation – Joseph D. Toscano, MD
Influenza Treatment – Paul G. Auwaerter, MD, MBA
Case Presentation – Joseph D. Toscano, MD
Wheel of Flu Knowledge – Frank LoVecchio, DO, MPH, FACEP

Faculty

Activity Chair:
Frank LoVecchio, DO, MPH, FACEP
Banner Good Samaritan Poison and Drug Information Center
Department of Emergency Medicine
Maricopa Integrated Health Systems
Professor, Research Scholar
University of Arizona and Creighton
College of Medicine
Phoenix, AZ
  • Disclosure: Royalty: UpToDate, Inc.


Faculty:
Paul G. Auwaerter, MD, MBA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure: Consulting Fee: DiaSorin, Shionogi
  • Ownership Interest: Johnson & Johnson


Jason E. Bowling, MD
Associate Professor
Department of Medicine, Division of Infectious Diseases
Director of Hospital Epidemiology, University Health System
UT Health San Antonio
San Antonio, TX
  • Disclosure: No relevant financial relationships to disclose.


Joseph D. Toscano, MD
Emergency Physician
Chief, Emergency Medicine
San Ramon Regional Medical Center
San Ramon, CA
  • Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
  • Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: January 15, 2020
Expires: January 14, 2021
45 minutes to complete

Provided By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is emergency medicine physicians and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate diagnostic assays into practice that have demonstrated improved sensitivity, specificity, and convenience to improve the detection of influenza.
  • Implement effective practices and procedures that reduce the spread of influenza in the hospital setting.
  • Utilize therapeutic regimens that effectively treat influenza as well as reduce its complications.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of children and adults in the United States each year. Emergency departments are a frequent point of entry for many influenza cases and are well-positioned to identify and manage influenza community outbreaks and epidemics. Clinical trials and observational data show that early antiviral treatment can shorten the duration of fever and illness symptoms and may reduce the risk of complications from influenza. Three classes of antiviral drugs are currently available for the prevention and treatment of influenza: neuraminidase inhibitors, adamantanes, and the polymerase inhibitor baloxavir marboxil. The faculty of this CME activity will explore existing and newer diagnostic methods for influenza as well as approved antiviral agents regarding their novel mechanisms of action, ability to reduce duration of clinical illness and complications, and cessation of viral shedding.

Agenda

Diagnosing Flu in the ED – Jason E. Bowling, MD
Case Presentation – Joseph D. Toscano, MD
Influenza Treatment – Paul G. Auwaerter, MD, MBA
Case Presentation – Joseph D. Toscano, MD
Wheel of Flu Knowledge – Frank LoVecchio, DO, MPH, FACEP

Faculty

Activity Chair:
Frank LoVecchio, DO, MPH, FACEP
Banner Good Samaritan Poison and Drug Information Center
Department of Emergency Medicine
Maricopa Integrated Health Systems
Professor, Research Scholar
University of Arizona and Creighton
College of Medicine
Phoenix, AZ
  • Disclosure: Royalty: UpToDate, Inc.


Faculty:
Paul G. Auwaerter, MD, MBA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure: Consulting Fee: DiaSorin, Shionogi
  • Ownership Interest: Johnson & Johnson


Jason E. Bowling, MD
Associate Professor
Department of Medicine, Division of Infectious Diseases
Director of Hospital Epidemiology, University Health System
UT Health San Antonio
San Antonio, TX
  • Disclosure: No relevant financial relationships to disclose.


Joseph D. Toscano, MD
Emergency Physician
Chief, Emergency Medicine
San Ramon Regional Medical Center
San Ramon, CA
  • Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
  • Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.25 CME
Vindico
Expanding Options in Influenza Management

Expanding Options in Influenza Management

Start

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: January 13, 2020
Expires: January 12, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Utilize evidence-based guidelines to diagnose influenza to improve earlier detection and treatment.
  • Compare currently available treatments for influenza based on their efficacy, effect on duration of virus, as well as the ability to improve outcomes for patients at normal and high risk for complications.
  • Implement best practices for prophylaxis, prevention, and treatment of influenza to reduce the duration of illness, viral shedding, and complications associated with the disease.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention estimates that influenza has resulted in 9.2 million to 35.6 million illnesses, 140,000 to 710,000 hospitalizations, and 12,000 to 56,000 deaths annually since 2010. Antiviral agents with different targets and mechanisms of action provide multiple therapeutic options and have promise of improving treatment effectiveness. In this continuing education activity, experts examine how to effectively diagnose and treat patients with influenza.

Faculty

Activity Chair:

Sanjay Sethi, MD
Professor and Chief
Pulmonary, Critical Care and Sleep Medicine
Assistant Vice President for Health Sciences
Department of Medicine
Jacobs School of Medicine & Biomedical Sciences
University of Buffalo
Buffalo, NY

Disclosure:
Consulting Fee: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pulmonx, Pulmotect
Speakers Bureau: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline


Faculty:

William A. Fischer II, MD
Assistant Professor of Medicine
Division of Pulmonary Diseases and Critical Care Medicine
Institute of Global Health and Infectious Diseases
University of North Carolina School of Medicine
Chapel Hill, NC

Disclosure:
Speaker Honoraria: Genentech


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 13, 2020 to January 12, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: January 13, 2020
Expires: January 12, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Utilize evidence-based guidelines to diagnose influenza to improve earlier detection and treatment.
  • Compare currently available treatments for influenza based on their efficacy, effect on duration of virus, as well as the ability to improve outcomes for patients at normal and high risk for complications.
  • Implement best practices for prophylaxis, prevention, and treatment of influenza to reduce the duration of illness, viral shedding, and complications associated with the disease.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention estimates that influenza has resulted in 9.2 million to 35.6 million illnesses, 140,000 to 710,000 hospitalizations, and 12,000 to 56,000 deaths annually since 2010. Antiviral agents with different targets and mechanisms of action provide multiple therapeutic options and have promise of improving treatment effectiveness. In this continuing education activity, experts examine how to effectively diagnose and treat patients with influenza.

Faculty

Activity Chair:

Sanjay Sethi, MD
Professor and Chief
Pulmonary, Critical Care and Sleep Medicine
Assistant Vice President for Health Sciences
Department of Medicine
Jacobs School of Medicine & Biomedical Sciences
University of Buffalo
Buffalo, NY

Disclosure:
Consulting Fee: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pulmonx, Pulmotect
Speakers Bureau: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline


Faculty:

William A. Fischer II, MD
Assistant Professor of Medicine
Division of Pulmonary Diseases and Critical Care Medicine
Institute of Global Health and Infectious Diseases
University of North Carolina School of Medicine
Chapel Hill, NC

Disclosure:
Speaker Honoraria: Genentech


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 13, 2020 to January 12, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 CME
Global Education Group
HIV in Aging Patients eHealth Source™ - HIV as a Chronic Disease: A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

HIV in Aging Patients eHealth Source™ - HIV as a Chronic Disease: A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credits
Released: July 15, 2019
Expires: July 15, 2020
60 minutes to complete

Jointly Provided by

Target Audience

This activity is intended for infectious disease and human immunodeficiency virus (HIV) specialist physicians and other clinicians involved in the care of patients with HIV infection.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Review the role of inflammation in the comorbidities commonly associated with HIV in aging patients
  • Tailor screening and treatment for common age-related HIV comorbidities, such as decreased bone mineral density and renal disease
  • Address CV risk in aging patients with HIV through selection of appropriate ART regimens and incorporation of recommended therapies to prevent CVD
  • Utilize knowledge of virus-related cancers to appropriately screen patients with HIV
  • Implement screening and appropriate treatment strategies for depression and HAND in aging patients with HIV

Activity Description

This HIV eHealth comprises 5 text-based chapters discussing common comorbidities seen in aging patients with HIV and supplemental videos that provide more detailed explanations of important concepts in HIV and aging as well as examples of best practices.

Statement of Educational Need

People with HIV (PWH) have a life expectancy that is only slightly shorter than that of the general population. In the United States, more than half of the 1.3 million PWH are older than 50 years—and the average age is rising.1 As PWH age, the risk of comorbidities and multimorbidity increases.2 The age-related multimorbidity seen in PWH is believed to be caused by HIV-associated chronic inflammation, immune dysregulation, and immune cell senescence.1 Comorbidity burden in aging PWH has a substantial negative effect on quality of life. Comorbidities of particular concern are cardiovascular disease, decreased bone mineral density, cancer, neurocognitive impairment and depression, and renal disease. These comorbidities may be influenced both by antiretroviral therapy (ART) and by HIV itself. There is a need for clinicians to better understand these comorbidities and form multidisciplinary teams to appropriately care for their aging patients with HIV. This HIV eHealth program includes epidemiology, pathophysiology, diagnosis, and management strategies for common comorbidities seen in aging PWH, including effect of ART on comorbidities and how each comorbidity may influence ART selection.

References

  • Wing EJ. HIV and aging. Int J Infect Dis. 2016;53:61-68.
  • Kendall CE, Wong J, Taljaard M, et al. A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario. BMC Public Health. 2014;14:161.

Agenda

Introduction
Chapter 1: Inflammation and Cardiovascular Disease Risk in HIV
Chapter 2: Bone Density and Osteoporosis Screening and Management
Chapter 3: HIV and Related Cancers
Chapter 4: Neurocognitive Impairment and Depression in HIV
Chapter 5: Renal Disease in Aging Patients With HIV

Faculty

Chris Longenecker, MD
Adult Cardiologist
Director, HIV Cardiometabolic Risk Clinic
University Hospitals Harrington Heart & Vascular Institute
Associate Professor of Medicine
Case Western Reserve University School of Medicine
Cleveland, Ohio


Paul E. Sax, MD
Professor of Medicine
Harvard Medical School
Clinical Director, Division of Infectious Diseases and HIV Program
Brigham and Women’s Hospital
Boston, Massachusetts


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Chris Longenecker, MD
Grant/Research Support: Gilead Sciences, Inc.

Paul E. Sax, MD
Consultant/Independent Contractor: AbbVie Inc., Bristol-Myers Squibb, Gilead Sciences, Inc., GlaxoSmithKline/ViiV Healthcare, Janssen Pharmaceuticals, Inc., Merck & Co., Inc.
Grant/ Research Support: Bristol-Myers Squibb, Gilead Sciences, Inc., GlaxoSmithKline/ViiV Healthcare, Merck & Co., Inc.

The following planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Gena Dolson, MS, Celeste Collazo, MD, Jim Kappler, PhD

Physicians Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physicians Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the posttest and program evaluation. Your posttest will automatically be graded. If you successfully complete the posttest (score of 80% or higher), your statement of participation will be made available immediately. Print the statement for your records. If you receive a score lower than 80%, you will receive a message notifying you that you did not pass the posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions about the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credits
Released: July 15, 2019
Expires: July 15, 2020
60 minutes to complete

Jointly Provided by

Target Audience

This activity is intended for infectious disease and human immunodeficiency virus (HIV) specialist physicians and other clinicians involved in the care of patients with HIV infection.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Review the role of inflammation in the comorbidities commonly associated with HIV in aging patients
  • Tailor screening and treatment for common age-related HIV comorbidities, such as decreased bone mineral density and renal disease
  • Address CV risk in aging patients with HIV through selection of appropriate ART regimens and incorporation of recommended therapies to prevent CVD
  • Utilize knowledge of virus-related cancers to appropriately screen patients with HIV
  • Implement screening and appropriate treatment strategies for depression and HAND in aging patients with HIV

Activity Description

This HIV eHealth comprises 5 text-based chapters discussing common comorbidities seen in aging patients with HIV and supplemental videos that provide more detailed explanations of important concepts in HIV and aging as well as examples of best practices.

Statement of Educational Need

People with HIV (PWH) have a life expectancy that is only slightly shorter than that of the general population. In the United States, more than half of the 1.3 million PWH are older than 50 years—and the average age is rising.1 As PWH age, the risk of comorbidities and multimorbidity increases.2 The age-related multimorbidity seen in PWH is believed to be caused by HIV-associated chronic inflammation, immune dysregulation, and immune cell senescence.1 Comorbidity burden in aging PWH has a substantial negative effect on quality of life. Comorbidities of particular concern are cardiovascular disease, decreased bone mineral density, cancer, neurocognitive impairment and depression, and renal disease. These comorbidities may be influenced both by antiretroviral therapy (ART) and by HIV itself. There is a need for clinicians to better understand these comorbidities and form multidisciplinary teams to appropriately care for their aging patients with HIV. This HIV eHealth program includes epidemiology, pathophysiology, diagnosis, and management strategies for common comorbidities seen in aging PWH, including effect of ART on comorbidities and how each comorbidity may influence ART selection.

References

  • Wing EJ. HIV and aging. Int J Infect Dis. 2016;53:61-68.
  • Kendall CE, Wong J, Taljaard M, et al. A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario. BMC Public Health. 2014;14:161.

Agenda

Introduction
Chapter 1: Inflammation and Cardiovascular Disease Risk in HIV
Chapter 2: Bone Density and Osteoporosis Screening and Management
Chapter 3: HIV and Related Cancers
Chapter 4: Neurocognitive Impairment and Depression in HIV
Chapter 5: Renal Disease in Aging Patients With HIV

Faculty

Chris Longenecker, MD
Adult Cardiologist
Director, HIV Cardiometabolic Risk Clinic
University Hospitals Harrington Heart & Vascular Institute
Associate Professor of Medicine
Case Western Reserve University School of Medicine
Cleveland, Ohio


Paul E. Sax, MD
Professor of Medicine
Harvard Medical School
Clinical Director, Division of Infectious Diseases and HIV Program
Brigham and Women’s Hospital
Boston, Massachusetts


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Chris Longenecker, MD
Grant/Research Support: Gilead Sciences, Inc.

Paul E. Sax, MD
Consultant/Independent Contractor: AbbVie Inc., Bristol-Myers Squibb, Gilead Sciences, Inc., GlaxoSmithKline/ViiV Healthcare, Janssen Pharmaceuticals, Inc., Merck & Co., Inc.
Grant/ Research Support: Bristol-Myers Squibb, Gilead Sciences, Inc., GlaxoSmithKline/ViiV Healthcare, Merck & Co., Inc.

The following planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Gena Dolson, MS, Celeste Collazo, MD, Jim Kappler, PhD

Physicians Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physicians Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the posttest and program evaluation. Your posttest will automatically be graded. If you successfully complete the posttest (score of 80% or higher), your statement of participation will be made available immediately. Print the statement for your records. If you receive a score lower than 80%, you will receive a message notifying you that you did not pass the posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions about the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

1.00 CME / CNE
American Heart Association
CASE STUDIES: Reducing Cardiovascular Risk in Patients with HIV

CASE STUDIES: Reducing Cardiovascular Risk in Patients with HIV

Start

Accredited By

American Heart Association

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: June 28, 2017
Expires: June 28, 2020
60 minutes to complete

Target Audience

Physicians (Cardiology, Family Practice, Infectious Disease, HIV Specialist and Internal Medicine); Physician Assistants (Cardiology, Family Practice, Infectious Disease, HIV Specialist, and Internal Medicine); Nurses/Nurse Practitioners; Other (Clinicians involved in the treatment and management of patients with HIV/AIDS)

Learning Objectives

1) State the CDC/USPSTF recommendation for universal opt-out HIV testing 2) Discuss preventive approaches to reduce risk of ASCVD in patients infected with HIV 3) Recognize the challenge of predicting cardiovascular risk in patients who are HIV-positive 4) Examine the treatment of ASCVD in patients who are HIV-positive

Activity Description

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Additionally, the program reviews epidemiologic patterns in HIV and the relevance of these for understanding the scope of CVD among HIV-infected individuals. Important concepts related to HIV screening and prevention, as well as CVD screening and prevention will be discussed; including new developments and existing barriers regarding CVD treatment for HIV-infected individuals will be reviewed. The activity uses a case-based format interspersed with didactic training to bridge the gap between theory and practice for practitioners caring for HIV-infected individuals.

Statement of Educational Need

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Agenda

45 minutes - Presentation of Case Studies: Reducing Cardiovascular Risk in Patients with HIV

15 minutes – Q & A

Presenters

Matthew J. Feinstein, MD
Assistant Professor of Medicine (Cardiology) and Preventive Medicine
Northwestern Medicine
Feinberg School of Medicine
Chicago, IL


David G. Weismiller, MD, ScM, FAAFP
Professor of Family Medicine
University of Nevada, Las Vegas
School of Medicine,
Las Vegas, NV


Planning Committee (Content Developers)

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Matthew J. Feinstein, MD
Matthew S. Freiberg, MD, MSc
Mark J. Haykowsky, PhD
Priscilla Hsue, MD
Wendy S. Post, MD, MS
David G. Weismiller, MD ScM, FAAFP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA – No Disclosures
Matthew J. Feinstein, MD – No Disclosures
Matthew S. Freiberg, MD, MSc – No Disclosures
Mark J. Haykowsky, PhD – No Disclosures
Priscilla Hsue, MD – Honoraria – Gilead; Research Grant – Pfizer; Other Research Support – Novartis
Wendy S. Post, MD, MS – No Disclosures
David G. Weismiller, MD ScM, FAAFP – No Disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 06/28/2017

TERMINATION DATE: 06/28/2020

LAST REVIEW DATE: June 2017

JOINT ACCREDITATION TERM: 06/28/2017 – 06/28/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

AAFP Credit Statement - Physicians
This Enduring Material activity, CASE STUDIES: Reducing Cardiovascular Risk in Patients with HIV, has been reviewed and is acceptable for up to 1.0 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 06/28/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation and Successful Completion

Successful completion of this CE activity includes the following: 

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 80%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Gilead Sciences.

Disclaimer Statement/ Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Luci Ochoa, MBA
Manager, Lifelong Learning, AHA National Center
luci.ochoa@heart.org

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Accredited By

American Heart Association

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: June 28, 2017
Expires: June 28, 2020
60 minutes to complete

Target Audience

Physicians (Cardiology, Family Practice, Infectious Disease, HIV Specialist and Internal Medicine); Physician Assistants (Cardiology, Family Practice, Infectious Disease, HIV Specialist, and Internal Medicine); Nurses/Nurse Practitioners; Other (Clinicians involved in the treatment and management of patients with HIV/AIDS)

Learning Objectives

1) State the CDC/USPSTF recommendation for universal opt-out HIV testing 2) Discuss preventive approaches to reduce risk of ASCVD in patients infected with HIV 3) Recognize the challenge of predicting cardiovascular risk in patients who are HIV-positive 4) Examine the treatment of ASCVD in patients who are HIV-positive

Activity Description

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Additionally, the program reviews epidemiologic patterns in HIV and the relevance of these for understanding the scope of CVD among HIV-infected individuals. Important concepts related to HIV screening and prevention, as well as CVD screening and prevention will be discussed; including new developments and existing barriers regarding CVD treatment for HIV-infected individuals will be reviewed. The activity uses a case-based format interspersed with didactic training to bridge the gap between theory and practice for practitioners caring for HIV-infected individuals.

Statement of Educational Need

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Agenda

45 minutes - Presentation of Case Studies: Reducing Cardiovascular Risk in Patients with HIV

15 minutes – Q & A

Presenters

Matthew J. Feinstein, MD
Assistant Professor of Medicine (Cardiology) and Preventive Medicine
Northwestern Medicine
Feinberg School of Medicine
Chicago, IL


David G. Weismiller, MD, ScM, FAAFP
Professor of Family Medicine
University of Nevada, Las Vegas
School of Medicine,
Las Vegas, NV


Planning Committee (Content Developers)

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Matthew J. Feinstein, MD
Matthew S. Freiberg, MD, MSc
Mark J. Haykowsky, PhD
Priscilla Hsue, MD
Wendy S. Post, MD, MS
David G. Weismiller, MD ScM, FAAFP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA – No Disclosures
Matthew J. Feinstein, MD – No Disclosures
Matthew S. Freiberg, MD, MSc – No Disclosures
Mark J. Haykowsky, PhD – No Disclosures
Priscilla Hsue, MD – Honoraria – Gilead; Research Grant – Pfizer; Other Research Support – Novartis
Wendy S. Post, MD, MS – No Disclosures
David G. Weismiller, MD ScM, FAAFP – No Disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 06/28/2017

TERMINATION DATE: 06/28/2020

LAST REVIEW DATE: June 2017

JOINT ACCREDITATION TERM: 06/28/2017 – 06/28/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

AAFP Credit Statement - Physicians
This Enduring Material activity, CASE STUDIES: Reducing Cardiovascular Risk in Patients with HIV, has been reviewed and is acceptable for up to 1.0 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 06/28/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation and Successful Completion

Successful completion of this CE activity includes the following: 

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 80%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Gilead Sciences.

Disclaimer Statement/ Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Luci Ochoa, MBA
Manager, Lifelong Learning, AHA National Center
luci.ochoa@heart.org

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME / CNE
American Heart Association
Cardiac Issues in HIV: Patient Cases

Cardiac Issues in HIV: Patient Cases

Start

Accredited By

American Heart Association

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: November 8, 2017
Expires: November 8, 2020
60 minutes to complete

Target Audience

Physicians (Cardiology, Family Practice, Infectious Disease, HIV Specialist and Internal Medicine); Physician Assistants (Cardiology, Family Practice, Infectious Disease, HIV Specialist, and Internal Medicine); Nurses/Nurse Practitioners; Other (Clinicians involved in the treatment and management of patients with HIV/AIDS)

Learning Objectives

1) Assess the clinical aspects of HIV-associated cardiovascular issues
2) Review the HIV-specific issues that are essential for management of CVD in the HIV-infected individual
3) Evaluate the management of CVD in the setting of HIV

Activity Description

This program will assess the clinical aspects of HIV-associated cardiovascular issues, review HIV-specific issues that are essential for the management of CVD in the HIV-infected individual as well as evaluate the management of CVD in the setting of HIV.

Statement of Educational Need

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Agenda

45 minutes - Cardiac Issues in HIV: Patient Cases

15 minutes – Q & A

Presenters

Priscilla Hsue, MD, FACC
William Watt Kerr Professor of Medicine
UCSF School of Medicine
San Francisco, CA


Wendy S. Post, MD, MS
Professor of Medicine and Epidemiology
Division of Cardiology, Department of Medicine
John Hopkins University School of Medicine and
Bloomberg School of Public Health


Planning Committee (Content Developers)

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Matthew J. Feinstein, MD
Matthew S. Freiberg, MD, MSc
Mark J. Haykowsky, PhD
Priscilla Hsue, MD
Wendy S. Post, MD, MS
David G. Weismiller, MD ScM, FAAFP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA – No Disclosures
Matthew J. Feinstein, MD – No Disclosures
Matthew S. Freiberg, MD, MSc – No Disclosures
Mark J. Haykowsky, PhD – No Disclosures
Priscilla Hsue, MD – Honoraria – Gilead; Research Grant – Pfizer; Other Research Support – Novartis
Wendy S. Post, MD, MS – No Disclosures
David G. Weismiller, MD ScM, FAAFP – No Disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 11/08/2017

TERMINATION DATE: 11/08/2020

LAST REVIEW DATE: September 2017

JOINT ACCREDITATION TERM: 11/08/2017 – 11/08/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

AAFP Credit Statement - Physicians
This Enduring Material activity, Cardiac Issues in HIV: Patient Cases, has been reviewed and is acceptable for up to 1.0 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 11/08/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation and Successful Completion

Successful completion of this CE activity includes the following: 

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 80%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Gilead Sciences.

Disclaimer Statement/ Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Luci Ochoa, MBA
Manager, Lifelong Learning, AHA National Center
luci.ochoa@heart.org

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Accredited By

American Heart Association

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: November 8, 2017
Expires: November 8, 2020
60 minutes to complete

Target Audience

Physicians (Cardiology, Family Practice, Infectious Disease, HIV Specialist and Internal Medicine); Physician Assistants (Cardiology, Family Practice, Infectious Disease, HIV Specialist, and Internal Medicine); Nurses/Nurse Practitioners; Other (Clinicians involved in the treatment and management of patients with HIV/AIDS)

Learning Objectives

1) Assess the clinical aspects of HIV-associated cardiovascular issues
2) Review the HIV-specific issues that are essential for management of CVD in the HIV-infected individual
3) Evaluate the management of CVD in the setting of HIV

Activity Description

This program will assess the clinical aspects of HIV-associated cardiovascular issues, review HIV-specific issues that are essential for the management of CVD in the HIV-infected individual as well as evaluate the management of CVD in the setting of HIV.

Statement of Educational Need

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Agenda

45 minutes - Cardiac Issues in HIV: Patient Cases

15 minutes – Q & A

Presenters

Priscilla Hsue, MD, FACC
William Watt Kerr Professor of Medicine
UCSF School of Medicine
San Francisco, CA


Wendy S. Post, MD, MS
Professor of Medicine and Epidemiology
Division of Cardiology, Department of Medicine
John Hopkins University School of Medicine and
Bloomberg School of Public Health


Planning Committee (Content Developers)

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Matthew J. Feinstein, MD
Matthew S. Freiberg, MD, MSc
Mark J. Haykowsky, PhD
Priscilla Hsue, MD
Wendy S. Post, MD, MS
David G. Weismiller, MD ScM, FAAFP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA – No Disclosures
Matthew J. Feinstein, MD – No Disclosures
Matthew S. Freiberg, MD, MSc – No Disclosures
Mark J. Haykowsky, PhD – No Disclosures
Priscilla Hsue, MD – Honoraria – Gilead; Research Grant – Pfizer; Other Research Support – Novartis
Wendy S. Post, MD, MS – No Disclosures
David G. Weismiller, MD ScM, FAAFP – No Disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 11/08/2017

TERMINATION DATE: 11/08/2020

LAST REVIEW DATE: September 2017

JOINT ACCREDITATION TERM: 11/08/2017 – 11/08/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

AAFP Credit Statement - Physicians
This Enduring Material activity, Cardiac Issues in HIV: Patient Cases, has been reviewed and is acceptable for up to 1.0 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 11/08/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation and Successful Completion

Successful completion of this CE activity includes the following: 

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 80%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Gilead Sciences.

Disclaimer Statement/ Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Luci Ochoa, MBA
Manager, Lifelong Learning, AHA National Center
luci.ochoa@heart.org

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME / CNE
American Heart Association
HIV and CVD: Beyond Coronary Heart Disease

HIV and CVD: Beyond Coronary Heart Disease

Start

Accredited By

American Heart Association

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: September 21, 2017
Expires: September 21, 2020
60 minutes to complete

Target Audience

Physicians (Cardiology, Family Practice, Infectious Disease, HIV Specialist and Internal Medicine); Physician Assistants (Cardiology, Family Practice, Infectious Disease, HIV Specialist, and Internal Medicine); Nurses/Nurse Practitioners; Other (Clinicians involved in the treatment and management of patients with HIV/AIDS)

Learning Objectives

1) Describe the general epidemiology of cardiovascular disease (CVD) related complications of human immunodeficiency virus (HIV) 2) Describe risk factors and mechanisms of atherosclerotic CVD in HIV 3) Describe approaches to predict, prevent, and treat atherosclerotic CVD in HIV 4) Review the scope of non-atherosclerotic CVD in HIV, as well as related mechanisms and treatment approaches

Activity Description

The program reviews epidemiologic patterns in HIV and the relevance of these for understanding the scope of CVD among HIV-infected individuals. Important concepts related to atherosclerotic and non-atherosclerotic cardiovascular diseases in people living with HIV, focusing on heart failure, arrhythmias and sudden cardiac death will be discussed; including new developments and existing barriers regarding CVD treatment for HIV-infected individuals.

Statement of Educational Need

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Agenda

45 minutes - HIV and CVD: Beyond Coronary Heart Disease Presentation

15 minutes – Q & A

Presenters

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Assistant Professor of Medicine & Global Health
Director, Cardiovascular Global Health
Duke University Medical Center
Duke Clinical Research Institute
Durham, NC 27705


Matthew S. Freiberg, MD, MSc
Director, Vanderbilt Center for Clinical Cardiovascular outcomes
Research And Trials Evaluation (V-C3REATE)
West End Home Foundation Scholar
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN


Planning Committee (Content Developers)

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Matthew J. Feinstein, MD
Matthew S. Freiberg, MD, MSc
Mark J. Haykowsky, PhD
Priscilla Hsue, MD
Wendy S. Post, MD, MS
David G. Weismiller, MD ScM, FAAFP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA – No Disclosures
Matthew J. Feinstein, MD – No Disclosures
Matthew S. Freiberg, MD, MSc – No Disclosures
Mark J. Haykowsky, PhD – No Disclosures
Priscilla Hsue, MD – Honoraria – Gilead; Research Grant – Pfizer; Other Research Support – Novartis
Wendy S. Post, MD, MS – No Disclosures
David G. Weismiller, MD ScM, FAAFP – No Disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/21/2017

TERMINATION DATE: 09/21/2020

LAST REVIEW DATE: June 2017

JOINT ACCREDITATION TERM: 09/21/2017 – 09/21/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

AAFP Credit Statement - Physicians
This Enduring Material activity, HIV and CVD: Beyond Coronary Heart Disease, has been reviewed and is acceptable for up to 1.0 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 09/21/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation and Successful Completion

Successful completion of this CE activity includes the following: 

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 80%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Gilead Sciences.

Disclaimer Statement/ Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Luci Ochoa, MBA
Manager, Lifelong Learning, AHA National Center
luci.ochoa@heart.org

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Accredited By

American Heart Association

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: September 21, 2017
Expires: September 21, 2020
60 minutes to complete

Target Audience

Physicians (Cardiology, Family Practice, Infectious Disease, HIV Specialist and Internal Medicine); Physician Assistants (Cardiology, Family Practice, Infectious Disease, HIV Specialist, and Internal Medicine); Nurses/Nurse Practitioners; Other (Clinicians involved in the treatment and management of patients with HIV/AIDS)

Learning Objectives

1) Describe the general epidemiology of cardiovascular disease (CVD) related complications of human immunodeficiency virus (HIV) 2) Describe risk factors and mechanisms of atherosclerotic CVD in HIV 3) Describe approaches to predict, prevent, and treat atherosclerotic CVD in HIV 4) Review the scope of non-atherosclerotic CVD in HIV, as well as related mechanisms and treatment approaches

Activity Description

The program reviews epidemiologic patterns in HIV and the relevance of these for understanding the scope of CVD among HIV-infected individuals. Important concepts related to atherosclerotic and non-atherosclerotic cardiovascular diseases in people living with HIV, focusing on heart failure, arrhythmias and sudden cardiac death will be discussed; including new developments and existing barriers regarding CVD treatment for HIV-infected individuals.

Statement of Educational Need

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Agenda

45 minutes - HIV and CVD: Beyond Coronary Heart Disease Presentation

15 minutes – Q & A

Presenters

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Assistant Professor of Medicine & Global Health
Director, Cardiovascular Global Health
Duke University Medical Center
Duke Clinical Research Institute
Durham, NC 27705


Matthew S. Freiberg, MD, MSc
Director, Vanderbilt Center for Clinical Cardiovascular outcomes
Research And Trials Evaluation (V-C3REATE)
West End Home Foundation Scholar
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN


Planning Committee (Content Developers)

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Matthew J. Feinstein, MD
Matthew S. Freiberg, MD, MSc
Mark J. Haykowsky, PhD
Priscilla Hsue, MD
Wendy S. Post, MD, MS
David G. Weismiller, MD ScM, FAAFP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA – No Disclosures
Matthew J. Feinstein, MD – No Disclosures
Matthew S. Freiberg, MD, MSc – No Disclosures
Mark J. Haykowsky, PhD – No Disclosures
Priscilla Hsue, MD – Honoraria – Gilead; Research Grant – Pfizer; Other Research Support – Novartis
Wendy S. Post, MD, MS – No Disclosures
David G. Weismiller, MD ScM, FAAFP – No Disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/21/2017

TERMINATION DATE: 09/21/2020

LAST REVIEW DATE: June 2017

JOINT ACCREDITATION TERM: 09/21/2017 – 09/21/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

AAFP Credit Statement - Physicians
This Enduring Material activity, HIV and CVD: Beyond Coronary Heart Disease, has been reviewed and is acceptable for up to 1.0 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 09/21/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation and Successful Completion

Successful completion of this CE activity includes the following: 

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 80%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Gilead Sciences.

Disclaimer Statement/ Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Luci Ochoa, MBA
Manager, Lifelong Learning, AHA National Center
luci.ochoa@heart.org

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.